| Autor: |
Su Zhang, Yong Zi Chen, Xiao Lin Zhu, Xi Hao Zhang, Ti Zhang, Dong Ming Liu, Lu Chen, Man Qing Cao, Zhi Wei Wang, Li Wei Chen, Hua Guo, Luo Yi, Hong Yuan Zhou, Zhen Yu Hou, Yun Long Cui, Ke Yun Zhu, Hui Kai Li, Xiao Ying Gu |
| Rok vydání: |
2020 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-72739/v2 |
| Popis: |
Anti-angiogenic drugs (AADs) are currently the main choice for systemic treatment of hepatocellular carcinoma, but treatment-related proteinuria can affect the routine use of AADs, which in turn affects the overall efficacy, its prevention is a clinical aspiration. At present, most clinicians give angiotensin-converting enzyme inhibitors (ACEIs) to alleviate proteinuria according to diabetic nephropathy guidelines or expert recommendations. However, its efficacy and whether it promotes cancer are controversial. Our clinical work has found that the use of ACEIs has not effectively relieved proteinuria, and some cases even have obvious tumor progression. Here we confirmed that in different tumor-bearing mouse models, ACEIs not only did not delay the appearance of proteinuria or reduce the degree of proteinuria caused by AADs, but also reduced the anti-cancer efficacy of AADs, and the reduction of anticancer efficacy has nothing to do with the change of VEGF signaling pathway, Our study show the combination of ACEIs and AADs aggravates the production of kidney-derived erythropoietin(EPO). In turn, EPO compromises the anti-angiogenic effects of AADs and decreases antitumor activity. This study presents treatment of proteinuria caused by AADs with ACEIs is useless and plays a role in drug resistance. Our purpose is to contribute to the rational management of side effects of AADs and to develop relevant guidelines. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
